Sugarbaker Touts New Clinical Study for Mesothelioma Patients

This study expands on what we already know about surgery and chemotherapy for mesothelioma, and combines them in a new way…with the goal of reducing recurrence rates and improving survival and quality of life,” Groth said in a press release from the Baylor Medical Center. “The heated chemotherapy fluid is effective at killing cancer and making the chemotherapy work better.” Baylor also has other ongoing mesothelioma clinical trials: A phase II study of anetumab ravtansine for patients with unresectable pleural mesothelioma and high expression of mesothelin, a vulnerable, tumor-surface protein linked to cancer progression and resistance to chemotherapy. Anetumab ravtansine is an immunotherapy/chemotherapy combination that binds to the mesothelin protein without harming the nonmesothelin cells. A phase I single-center trial measuring the effectiveness of the immunotherapy drugs durvalumab and tremelimumab used in conjunction with aggressive surgery. The drugs will be given two to three weeks before surgery, prompting a patient’s own immune system to begin attacking the tumor before the operation. “This one [cisplatin/pemetrexed] is pretty straight forward,” Sugarbaker said. “I would advise patients to consider this protocol very carefully. Patients have a few studies here to choose from, and determine in which one they would be most comfortable.” The post Sugarbaker Touts New Clinical Study for Mesothelioma Patients appeared first on Mesothelioma Center - Vi...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: baylor college of medicine chemotherapy for mesothelioma dr. david sugarbaker mesothelioma chemotherapy drugs mesothelioma clinical trial mesothelioma treatment center at baylor Source Type: news